Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Stephen J. Greene"'
Autor:
Jacob B. Pierce, Muthiah Vaduganathan, Gregg C. Fonarow, Uchechukwu Ikeaba, Karen Chiswell, Javed Butler, Adam D. DeVore, Paul A. Heidenreich, Joanna C. Huang, Michelle M. Kittleson, Karen E. Joynt Maddox, Karthik K. Linganathan, James J. McDermott, Anjali Tiku Owens, Pamela N. Peterson, Scott D. Solomon, Orly Vardeny, Clyde W. Yancy, Stephen J. Greene
Publikováno v:
JAMA Cardiology.
ImportanceClinical guidelines for patients with heart failure with reduced ejection fraction (HFrEF) strongly recommend treatment with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) to reduce cardiovascular mortality or HF hospitalization. Natio
Autor:
Jamie Diamond, Iyanuoluwa Ayodele, Gregg C. Fonarow, Karen E. Joynt-Maddox, Robert W. Yeh, Gmerice Hammond, Larry A. Allen, Stephen J. Greene, Karen Chiswell, Adam D. DeVore, Clyde Yancy, Rishi K. Wadhera
Publikováno v:
JAMA Cardiology.
ImportanceBlack adults with heart failure (HF) disproportionately experience higher population-level mortality than White adults with HF. Whether quality of care for HF differs at hospitals with high proportions of Black patients compared with other
Autor:
Jacob B. Pierce, Uchechukwu Ikeaba, Anthony E. Peters, Adam D. DeVore, Karen Chiswell, Larry A. Allen, Nancy M. Albert, Clyde W. Yancy, Gregg C. Fonarow, Stephen J. Greene
Publikováno v:
JAMA Cardiology. 8:376
ImportancePrior studies have suggested patients with heart failure (HF) from rural areas have worse clinical outcomes. Contemporary differences between rural and urban hospitals in quality of care and clinical outcomes for patients hospitalized for H
Autor:
Stephen J. Greene, Muthiah Vaduganathan, Brian Claggett, Ankeet S. Bhatt, Rahul Aggarwal, Gregg C. Fonarow, Scott D. Solomon, John J.V. McMurray
Publikováno v:
JAMA Cardiology. 6:1415
Importance The US Food and Drug Administration (FDA) expanded labeling for sacubitril/valsartan for use in individuals with chronic heart failure (HF) with left ventricular ejection fraction (LVEF) lower than normal. The population-level implications
Publikováno v:
JAMA Cardiology. 6:743
Autor:
Muthiah Vaduganathan, Pamela S. Douglas, Roxana Mehran, Stephen J. Greene, Ayman Samman Tahhan, Gregg C. Fonarow, Mohamed Raad, Javed Butler, M. Mazen Gafeer, Deepak L. Bhatt, Alaaeddin Alrohaibani
Publikováno v:
JAMA Cardiology. 5:714
Importance Although age, sex, and race/ethnicity are important factors when generalizing the findings of clinical trials to routine practice, trends in the representation of these groups in contemporary acute coronary syndrome (ACS) trials are not we
Autor:
Warren K. Laskey, Melissa A. Greiner, Steven J. Lippmann, Marc D. Samsky, Stephen J. Greene, Robert J. Mentz, Li Lin, Emily C. O'Brien, Abhishek Kavati, Gregg C. Fonarow, Clyde W. Yancy, Paul A. Heidenreich, N. Chantelle Hardy, Pamela N. Peterson, Siyeon Park
Publikováno v:
JAMA Cardiol
Importance There are major gaps in use of guideline-directed medical therapy (GDMT) for patients with heart failure (HF). Patient-reported data outlining patient goals and preferences associated with GDMT are not available. Objective To survey patien
Autor:
Javed Butler, Stephen J. Greene, Muthiah Vaduganathan, Mona Fiuzat, Christopher M. O'Connor, Mariell Jessup, JoAnn Lindenfeld, Gregg C. Fonarow, Ayman Samman Tahhan
Publikováno v:
JAMA Cardiology. 3:1011
Despite the importance of age, sex, and race/ethnicity representativeness in clinical trials, limited data exist regarding the enrollment trends of these groups in contemporary heart failure (HF) trials.To characterize the representation of older pat
Publikováno v:
JAMA Cardiology. 3:252
Importance Hospitalizations for worsening heart failure (WHF) represent an enormous public health and financial burden, with physicians, health systems, and payers placing increasing emphasis on hospitalization prevention. In addition, maximizing tim
Publikováno v:
JAMA. 311:1446
The Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE) trial1 contributes to the body of evidence supporting an improved safety profile of second-generation drug